Yun Yen - 30 Jun 2024 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Issuer symbol
LIXT
Transactions as of
30 Jun 2024
Transactions value $
$0
Form type
4
Filing time
02 Jul 2024, 18:27:27 UTC
Previous filing
07 Jul 2023
Next filing
29 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +10K $0.00 10K 30 Jun 2024 Common 10K $2.37 Direct F1
transaction LIXT Options to Purchase Common Stock Award $0 +4.53K $0.00 4.53K 30 Jun 2024 Common 4.53K $2.37 Direct F2
holding LIXT Options to Purchase Common Stock 10K 30 Jun 2024 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K 30 Jun 2024 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K 30 Jun 2024 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 5.26K 30 Jun 2024 Common 5.26K $57.00 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 3.33K 30 Jun 2024 Common 3.33K $16.80 Direct
holding LIXT Options to Purchase Common Stock 833 30 Jun 2024 Common 833 $66.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2024).
F2 Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 4,527 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the Reporting Person under the Board Compensation Plan.